Tamarack Advisers, LP - RIGEL PHARMACEUTICALS INC ownership

RIGEL PHARMACEUTICALS INC's ticker is RIGL and the CUSIP is 766559603. A total of 129 filers reported holding RIGEL PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 0.36 and the average weighting 0.1%.

Quarter-by-quarter ownership
Tamarack Advisers, LP ownership history of RIGEL PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2023$1,612,500
-38.9%
1,250,000
-37.5%
0.50%
-48.4%
Q1 2023$2,640,000
-23.5%
2,000,000
-13.0%
0.96%
-45.7%
Q4 2022$3,450,000
+46.2%
2,300,000
+15.0%
1.78%
+28.2%
Q3 2022$2,360,000
+4.4%
2,000,0000.0%1.39%
+6.0%
Q2 2022$2,260,000
-76.7%
2,000,000
-38.5%
1.31%
-71.6%
Q1 2022$9,718,000
-18.5%
3,250,000
-27.8%
4.60%
-6.2%
Q4 2021$11,925,000
-53.3%
4,500,000
-35.8%
4.90%
-39.1%
Q3 2021$25,510,000
-8.2%
7,005,000
+9.5%
8.06%
+2.4%
Q2 2021$27,776,000
-2.7%
6,400,000
-23.4%
7.87%
+34.3%
Q1 2021$28,557,000
+10.0%
8,350,000
+12.1%
5.86%
+8.3%
Q4 2020$25,963,000
+44.2%
7,450,000
-0.7%
5.41%
-2.5%
Q3 2020$18,000,000
+43.6%
7,500,000
+9.5%
5.55%
+58.9%
Q2 2020$12,536,000
+44.8%
6,850,000
+23.4%
3.49%
+6.4%
Q1 2020$8,658,000
-26.6%
5,550,000
-3.5%
3.28%
+21.8%
Q4 2019$11,788,000
+15.1%
5,750,000
+5.0%
2.69%
+0.9%
Q3 2019$10,238,000
-27.0%
5,475,0000.0%2.67%
-37.4%
Q2 2019$14,016,000
+2.9%
5,475,000
+3.3%
4.26%
-21.2%
Q1 2019$13,621,000
+7.7%
5,300,000
-3.6%
5.41%
+4.8%
Q4 2018$12,650,000
-13.4%
5,500,000
+20.9%
5.16%
+23.7%
Q3 2018$14,606,000
+96.6%
4,550,000
+73.3%
4.17%
+67.7%
Q2 2018$7,429,0002,625,0002.49%
Other shareholders
RIGEL PHARMACEUTICALS INC shareholders Q2 2019
NameSharesValueWeighting ↓
GREAT POINT PARTNERS LLC 9,105,691$30,140,0005.99%
Sio Capital Management, LLC 1,888,181$6,250,0003.50%
DAFNA Capital Management LLC 473,478$1,567,0001.32%
Cormorant Asset Management, LP 2,000,000$6,620,0000.96%
Ghost Tree Capital, LLC 1,100,000$3,641,0000.68%
Rhenman & Partners Asset Management AB 1,282,000$4,243,0000.67%
Palo Alto Investors LP 4,254,623$14,083,0000.67%
NEA Management Company, LLC 3,243,150$10,375,0000.36%
Telemetry Investments, L.L.C. 170,000$563,0000.25%
NJ State Employees Deferred Compensation Plan 355,000$1,175,0000.22%
View complete list of RIGEL PHARMACEUTICALS INC shareholders